|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.22 AUD | -1.32% |
|
-7.38% | -33.84% |
| 07-22 | Daily Special: Altoro Metals, Carnegie Clean Energy, Mastermyne Group, Eden Innovations, Stelar Metals | FI |
| 07-21 | ASX Midday Sector Update: Materials Stocks Jump, Healthcare Sector Struggles | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
CSL Behring (Incl.CSL Intellectual Property) | 8.57B | 8.6B | 9.29B | 10.61B | 11.16B | |||||
Total Assets | 15.91B | 25.88B | 34.54B | 23.64B | 24.5B | |||||
CAPEX | -1.51B | -1.08B | -869M | -615M | -505M | |||||
Gross Profit | 4.85B | 4.58B | 4.58B | 5.28B | 5.64B | |||||
EBITDA | 3.15B | 2.76B | 4.07B | 4.71B | 5.04B | |||||
D&A | 410M | 443M | 273M | 337M | 335M | |||||
Operating Income | 2.65B | 2.19B | 3.79B | 4.37B | 4.7B | |||||
Csl Vifor | - | - | 1.99B | 2.06B | 2.23B | |||||
Total Assets | - | - | 10.74B | 9.98B | 10.24B | |||||
CAPEX | - | - | -33M | -22M | -12M | |||||
Gross Profit | - | - | 1.41B | 1.41B | 1.54B | |||||
EBITDA | - | - | 954M | 988M | 1.13B | |||||
D&A | - | - | 24M | 25M | 23M | |||||
Operating Income | - | - | 921M | 956M | 1.1B | |||||
CSL Seqirus | 1.74B | 1.96B | 2.03B | 2.13B | 2.17B | |||||
Total Assets | 2.57B | 3.04B | 5.91B | 4.4B | 4.67B | |||||
CAPEX | -155M | -165M | -326M | -212M | -119M | |||||
Gross Profit | 996M | 1.15B | 1.26B | 1.32B | 1.26B | |||||
EBITDA | 569M | 834M | 1.16B | 1.2B | 1.11B | |||||
D&A | 85.3M | 99.2M | 60M | 60M | 59M | |||||
Operating Income | 483M | 735M | 1.08B | 1.12B | 1.03B | |||||
CSL Behring | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBITDA | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Pharmaceutical Products | ||||||||||
Operating Income | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBITDA | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Operating Income | - | - | -907M | -825M | -1B | |||||
D&A | - | - | - | 106M | 132M | |||||
Operating Income | - | - | -1.23B | -1.43B | -1.36B | |||||
Total Assets | -324M | -577M | -14.95B | - | - | |||||
EBITDA | - | - | -2.28B | -2.15B | -2.12B | |||||
Operating Income | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
EBITDA | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 4.98B | 5.12B | 6.56B | 7.29B | 7.31B | |||||
Total Assets | 3.54B | 3.95B | 4.28B | 4.35B | 4.35B | |||||
Rest of World | 2.08B | 2.01B | 2.85B | 3.92B | 4.45B | |||||
Total Assets | 445M | 431M | 357M | 350M | 344M | |||||
Germany | 854M | 781M | 869M | 873M | 947M | |||||
Total Assets | 1.09B | 1.23B | 1.27B | 1.31B | 1.29B | |||||
Australia | 859M | 1.02B | 1.04B | 900M | 890M | |||||
Total Assets | 1.44B | 1.42B | 1.92B | 2.15B | 2.29B | |||||
China and Hong Kong | 651M | 745M | 779M | 747M | 849M | |||||
Total Assets | 484M | 482M | 80M | 17M | 17M | |||||
United Kingdom | 580M | 596M | 717M | 744M | 807M | |||||
Total Assets | 417M | 331M | 329M | 332M | 397M | |||||
Switzerland | 307M | 282M | 488M | 318M | 302M | |||||
Total Assets | 2.79B | 3.1B | 9.48B | 9.42B | 9.22B |
- Stock Market
- Stocks
- CSL Stock
- Financials CSL Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
















